Anna Kalogeropoulos, DO
Family Medicine · Denver, CONPI 1942614102
Payments from drug & device makers
Across 180 payments — averaging $18.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- AstraZeneca$445
- Lilly USA, LLC$396
- GSK$308
- Grifols USA, LLC$180
- Amgen$157
- plus $677 from 19 others
What the payments were for
- Food & beverage$3,251100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 55 | $1,087 |
| AstraZeneca | 27 | $445 |
| Lilly USA, LLC | 25 | $396 |
| GSK | 17 | $308 |
| Grifols USA, LLC | 8 | $180 |
| Amgen | 8 | $157 |
| Vanda Pharmaceuticals Inc. | 4 | $70 |
| Eisai Inc. | 5 | $67 |
| Teva Pharmaceuticals USA, Inc. | 2 | $54 |
| Boehringer Ingelheim | 3 | $52 |
| Novo Nordisk | 3 | $50 |
| Johnson & Johnson | 3 | $47 |
| Nestle Healthcare Nutrition Inc. | 3 | $41 |
| Corium, LLC | 2 | $39 |
| Ironshore Pharmaceuticals Inc. | 1 | $35 |
| Idorsia Pharmaceuticals US Inc | 2 | $34 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $34 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $30 |
| Merck | 2 | $28 |
| Pfizer | 1 | $20 |
| Biodelivery Sciences International, Inc. | 1 | $18 |
| Aimmune Therapeutics, Inc. | 1 | $16 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $15 |
| Biohaven Pharmaceuticals, Inc. | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
How this compares
$3,251 in reported general payments places this provider in the 90th percentile of 2,079 family medicine providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 31 | $26,307 |
| OzempicSemaglutide | 21 | $23,087 |
| TrulicityDulaglutide | 14 | $23,002 |
| FarxigaDapagliflozin Propanediol | 31 | $22,878 |
| EliquisApixaban | 26 | $21,046 |
| LinzessLinaclotide | 24 | $18,409 |
| VraylarCariprazine Hcl | 12 | $16,757 |
| Spiriva HandihalerTiotropium Bromide | 15 | $14,836 |
| MounjaroTirzepatide | 11 | $12,086 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 14 | $11,871 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 15 | $10,282 |
| Repatha SureclickEvolocumab | 14 | $8,076 |
| TrintellixVortioxetine Hydrobromide | 12 | $6,247 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 143 | $4,483 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 20 | $3,313 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLinzess, Vraylar, Synthroid | $1,087 | $35,69453 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $396 | $35,08725 claims |
| Johnson & JohnsonXarelto | $47 | $26,30731 claims |
| Novo NordiskOzempic | $50 | $23,08721 claims |
| AstraZenecaFarxiga | $445 | $22,87831 claims |
| PfizerEliquis | $20 | $21,04626 claims |
| Boehringer IngelheimCombivent Respimat | $52 | $11,87114 claims |
| GSKTrelegy Ellipta | $308 | $10,28215 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $30 | $6,24712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,079 family medicine providers in Colorado.
Other family medicine in Denver
- Mia ScottDenver$993K
- Ethan LazarusDenver$688K
- Judith ShlayDenver$264K
- Mark DeutchmanDenver$258K
- Johnny ShenDenver$182K
- Flory KreutterDenver$118K
- Nathaniel MooreDenver$21K
- Clint FlanaganDacono$7.6M
- Larry OdekirkCastle Rock$6.3M
- Ripley HollisterColorado Springs$5.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.